CN112010875A - 基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 - Google Patents
基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 Download PDFInfo
- Publication number
- CN112010875A CN112010875A CN202010989968.7A CN202010989968A CN112010875A CN 112010875 A CN112010875 A CN 112010875A CN 202010989968 A CN202010989968 A CN 202010989968A CN 112010875 A CN112010875 A CN 112010875A
- Authority
- CN
- China
- Prior art keywords
- complex
- copper
- methoxy
- acetone
- schiff base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 title claims abstract description 30
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 239000002262 Schiff base Substances 0.000 title claims abstract description 16
- -1 methoxy salicylidene amino triazole Schiff base Chemical class 0.000 title claims abstract description 10
- 238000001308 synthesis method Methods 0.000 title abstract description 12
- 239000011521 glass Substances 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 239000013078 crystal Substances 0.000 claims abstract description 11
- RZQQXRVPPOOCQR-UHFFFAOYSA-N 2,3-dihydro-1,3,4-oxadiazole Chemical compound C1NN=CO1 RZQQXRVPPOOCQR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims abstract description 6
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 4
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims abstract description 3
- 239000010949 copper Substances 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229910021645 metal ion Inorganic materials 0.000 abstract description 2
- 239000000575 pesticide Substances 0.000 abstract description 2
- 238000011065 in-situ storage Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- MTBSFYGHHCAQIY-UHFFFAOYSA-N O1NC=CC=C1.O1N=NC=C1 Chemical compound O1NC=CC=C1.O1N=NC=C1 MTBSFYGHHCAQIY-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
本发明公开了基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(Ⅰ)配合物及其合成方法,合成方法包括下述步骤:(1)称取3‑甲氧基水杨醛缩‑3‑氨基‑1,2,4‑三氮唑席夫碱8‑12 mg,CuCl 4‑6 mg或CuBr 6‑8 mg于一端封口的玻璃管中,并加入1.0‑3.0mL丙酮,震荡,使其充分混合;再放置真空条件下将玻璃管的另一端密封;(2)将上述密封的玻璃管置于110‑130℃烘箱中反应,反应60‑80小时后停止加热,然后以每小时10℃降温至室温,得到无色长条状晶体,即铜(Ⅰ)配合物产物。本发明产物中的7‑甲氧基‑5‑甲基‑3,11‑二氢‑5H‑5,11‑甲基苯并[g][1,2,4]***并[1,5‑c][1,3,5]恶二唑嗪是一种新型的多环化合物,可作为中间体应用于医药、农药等领域,其与金属离子形成配合物有较好的抗菌与抗癌活性,具有重要的潜在用途。
Description
技术领域
本发明涉及铜配合物及其原位合成方法,具体是基于丙酮和3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱的铜(Ⅰ)配合物及其原位合成方法。
背景技术
近年来出现的原位合成技术,广泛应用于化学、化工、材料等领域。原位合成是指在一定条件下,通过化学反应,在反应体系内原位生成一种或几种新型的化合物。通过原位合成,可以获得其他合成方法难以获得的化合物。
目前虽有不少文献报道了原位配体反应,但未见有3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱(见(1)式)与溶剂丙酮发生反应生成7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c] [1,3,5]恶二唑嗪(简写为HL,其结构见(2)式),进而生成铜(Ⅰ)配合物的报导。
所述的3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱的结构式如(1)式所示:
所述的7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c][1,3,5]恶二唑嗪(HL)的结构式如(2)式所示:
发明内容
为了获得新的7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g][1,2,4]
***并[1,5-c][1,3,5]恶二唑嗪配合物,本发明公开了以丙酮和3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱为原料的两种铜(Ⅰ) 配合物及这两种配合物的原位合成方法。
本发明第一种,基于丙酮和3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱的铜(Ⅰ)配合物,化学式为[Cu(HL)2Cl],其中 HL=7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c] [1,3,5]恶二唑嗪,配合物晶体属于正交晶系,P21212空间群,晶胞参数为:a =31.193(4) Å,b = 5.7128(8)Å ,c =7.3358(11)Å,α= 90.00º,β=90.00º,γ= 90.00º,V = 1307.2 (3) Å3;
配合物的分子结构式如(3)式所示:
本发明第二种,基于丙酮和3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱的配合物,化学式为[Cu(HL)2Br],其中 HL=7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c] [1,3,5]恶二唑嗪,配合物晶体属于正交晶系,P21212空间群,晶胞参数为:a =31.435(10) Å,b = 5.6531(19)Å ,c =7.520(3)Å,α= 90.00º,β=90.00º,γ= 90.00º,V = 1336.3 (8) Å3;
配合物的分子结构式如(4)式所示:
所述两种配合物的合成路线为:
X=Cl, Br 。
所述第一种配合物[Cu(HL)2Cl]的原位合成方法,包括下述步骤:
(1)称取 3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱8-12 mg,CuCl 4-6 mg于一端封口的玻璃管中,并加入 1.0-3.0mL丙酮,震荡,使其充分混合;再放置真空条件下将玻璃管的另一端密封;
(2) 将上述密封的玻璃管置于110-130℃烘箱中反应,反应60-80小时后停止加热,然后以每小时10°C降温至室温,得到无色长条状晶体,即Cu(HL)2Cl]产物。
所述第二种配合物[Cu(HL)2Br]的原位合成方法,用CuBr 6-8 mg取代第一种配合物[Cu(HL)2Cl]合成方法中的CuCl,其它条件不变,同样也得到无色长条状晶体,即[Cu(HL)2Br]产物。
从两种配合物的合成路线可以看出,溶剂丙酮与3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱发生了加成反应,然后脱掉一分子水H2O,生成7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c] [1,3,5]恶二唑嗪(HL),进而与金属铜(Ⅰ)配位。
本发明产物中的7-甲氧基-5-甲基-3,11-二氢-5H-5,11-甲基苯并[g] [1,2,4]***并[1,5-c] [1,3,5]恶二唑嗪是一种新型的多环化合物,可作为中间体应用于医药、农药等领域,其与金属离子形成配合物有较好的抗菌与抗癌活性,具有重要的潜在用途。
本发明两种配合物的原位合成方法,具有原料易得、成本低廉、工艺简单等优点。此外,还用MTT 比色法初步测定了本发明两种配合物对部分细胞株的IC50值,结果表明,本发明两种配合物具有一定的抗肿瘤活性。
附图说明
图1 实施例1配合物[Cu(HL)2Cl]的分子结构图(省略了氢原子);
图2 实施例2配合物[Cu(HL)2Br]的分子结构图(省略了氢原子)。
具体实施方式
下面结合实施例对本发明内容作进一步的说明,但不是对本发明的限定。
实施例1
配合物[Cu(HL)2Cl]的原位合成方法,包括下述步骤:
(1)分别称取 3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱10.9mg (0.05 mmol)、CuCl 5.0 mg (0.05 mmol)于长约19 cm 内径为1.0 cm 一端封口的玻璃管中,并加入 2.0mL 丙酮,震荡,使其充分混合;再放置真空条件下将玻璃管的另一端密封;
(2)将上述密封的玻璃管置于120 ℃烘箱中反应,反应72小时后停止加热,然后以每小时10°C降温至室温,得到无色长条状晶体,即[Cu(HL)2Cl]产物,产率为41.2%。
参见图1,从图中可以看出,实施例1配合物的最小单元中仅有一个晶体学上独立的Cu(Ⅰ)离子,该中心铜(Ⅰ)离子分别与1个氯原子Cl和来自两个配体(HL)上的各1个N原子配位,形成化学式为[Cu(HL)2Cl]的配合物。该配合物的最小结构单元通过弱键相互作用,构成三维晶体结构。
实施例2
配合物[Cu(HL)2Br]的原位合成方法,用CuBr7.2 mg (0.05 mmol)取代实施例1中的CuCl,其它条件不变,同样也得到无色长条状晶体,即[Cu(HL)2Br]产物,产率为43.5%,分子结构见图2,该结构与图1的区别仅在于由Br原子取代了Cl原子。
实施例3
用MTT 比色法测定实施例两种配合物对部分细胞株的IC50值,如表1所示,表中HL-7702为人正常的肝细胞株、A549为人肺癌细胞株、T-24为人膀胱癌细胞株、MGC80-3为人胃癌细胞株。
表1、实施例配合物对不同细胞株的IC50值(μM)
表1的结果表明,实施例两种配合物具有一定的抗肿瘤活性。
Claims (4)
4.根据权利要求3所述的铜(Ⅰ)配合物的合成方法,其特征在于,合成方法包括下述步骤:
(1)称取 3-甲氧基水杨醛缩-3-氨基-1,2,4-三氮唑席夫碱8-12 mg,CuCl 4-6 mg或CuBr 6-8 mg于一端封口的玻璃管中,并加入 1.0-3.0mL丙酮,震荡,使其充分混合;再放置真空条件下将玻璃管的另一端密封;
(2) 将上述密封的玻璃管置于110-130℃烘箱中反应,反应60-80小时后停止加热,然后以每小时10℃降温至室温,得到无色长条状晶体,即铜(Ⅰ)配合物产物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010989968.7A CN112010875B (zh) | 2020-09-19 | 2020-09-19 | 基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010989968.7A CN112010875B (zh) | 2020-09-19 | 2020-09-19 | 基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112010875A true CN112010875A (zh) | 2020-12-01 |
CN112010875B CN112010875B (zh) | 2023-02-07 |
Family
ID=73522096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010989968.7A Active CN112010875B (zh) | 2020-09-19 | 2020-09-19 | 基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112010875B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100204467A1 (en) * | 2007-07-18 | 2010-08-12 | Cis Bio International | Lanthanide (iii) ion complexing compounds, luminescent lanthanide (iii) ion complexes and use thereof as fluorescent labels |
CN106397461A (zh) * | 2016-09-13 | 2017-02-15 | 桂林理工大学 | 磁性材料水杨醛衍生物席夫碱铜配合物[Cu4(emdo)4]·H2O及合成方法 |
-
2020
- 2020-09-19 CN CN202010989968.7A patent/CN112010875B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100204467A1 (en) * | 2007-07-18 | 2010-08-12 | Cis Bio International | Lanthanide (iii) ion complexing compounds, luminescent lanthanide (iii) ion complexes and use thereof as fluorescent labels |
CN106397461A (zh) * | 2016-09-13 | 2017-02-15 | 桂林理工大学 | 磁性材料水杨醛衍生物席夫碱铜配合物[Cu4(emdo)4]·H2O及合成方法 |
Non-Patent Citations (2)
Title |
---|
NIKOLAY YU. GOROBETS等: "Unexpected alternative direction of a Biginelli-like multicomponent reaction with 3-amino-1,2,4-triazole as the urea component", 《TETRAHEDRON LETTERS》 * |
高霞等: "1,5-双(苯并三氮唑)戊烷钬配合物的抑菌性研究", 《化学工程与装备》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112010875B (zh) | 2023-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duchateau et al. | Side-on versus end-on coordination of dinitrogen to titanium (II) and mixed-valence titanium (I)/titanium (II) amido complexes | |
Liu et al. | A two-dimensional network constructed via 72-membered heart-shaped macrocycles, a copper (II) complex with 1, 3, 5-tris (imidazol-1-ylmethyl)-2, 4, 6-trimethylbenzene and diethylenetriamine ligands | |
Wu et al. | Synthesis and structure of a three-dimensional copper (II) coordination polymer with 1, 2-bis (imidazol-1′-yl) ethane | |
JP5437554B2 (ja) | 多孔性金属錯体の製造方法、多孔性金属錯体、吸着材、分離材、ガス吸着材及び水素吸着材 | |
Thakker et al. | Synthetic control of the cis/trans geometry of [M (cyclam)(CCR) 2] OTf complexes and photophysics of cis-[Cr (cyclam)(CCCF3) 2] OTf and cis-[Rh (cyclam)(CCCF3) 2] OTf | |
Ranjbar et al. | Crystal structure of Bi (III) complex of a pyridine containing self-assembling system | |
Ghilardi et al. | Hydridodinitrogen and hydrido complexes of iron (II) with the linear tetratertiary phosphine hexaphenyl-1, 4, 7, 10-tetraphosphadecane. Crystal structure of the complex [FeH (N2)((C6H5) 2PC2H4P (C6H5) C2H4P (C6H5) C2H4P (C6H5) 2] Br· C2H5OH | |
CN111961069B (zh) | 基于丙酮和水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 | |
CN112010875B (zh) | 基于丙酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 | |
CN112010874B (zh) | 基于丁酮和水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 | |
CN112010876B (zh) | 基于丁酮和甲氧基水杨醛缩氨基三氮唑席夫碱的铜(ⅰ)配合物及其合成方法 | |
Fernández et al. | Sterically controlled reactivity of palladium (ii) tetranuclear cyclometallated complexes. Crystal and molecular structure of the novel tetranuclear compound [Pd 2 {1, 3-[C (H)[double bond, length half m-dash] NCH 2 C 4 H 7 O] 2 C 6 H 2}(μ-Cl)(Cl)(PPh 3)] 2 | |
Gemel et al. | Synthesis and characterization of ruthenium quinolin-8-olate complexes. Unexpected formation of a κ 1-hydrotris (pyrazolyl) borate complex | |
Buckingham et al. | Reactions of coordinated nucleophiles. Formation and structure of a novel tridentate complex | |
Troyanov | Copper and calcium complexes with the anionic O 2-donor 4-tert-butylacetyl-3-methyl-1-phenylpyrazol-5-onato (Q–). Influence of hydrogen-bond interactions on lattice architecture in the crystal structures of [CuQ 2 (H 2 O)] and [CaQ 2 (EtOH) 2] | |
Whited et al. | Complexes of iron and cobalt with new tripodal amido-polyphosphine hybrid ligands | |
Wang et al. | 1, 2, 4-Diazaphospholide complexes of yttrium (iii), dysprosium (iii), erbium (iii), and europium (ii, iii): synthesis, X-ray structural characterization, and EPR analysis | |
Delgado et al. | Synthesis and structural characterization of copper (II) bishexafluoroacetylacetonate complexes with N-donor ligands | |
Chatt et al. | Hydrazido (2–)-complexes of tungsten-(V) and-(VI) and a bis (diazenido)-complex of tungsten (IV). X-Ray crystal structure of cis-[WCl 3 (NNH 2)(PMe 2 Ph) 2] | |
Patel et al. | Tris (mercaptoimidazolyl) borate complexes of the coinage metals: syntheses and molecular structures of the first gold compounds and related copper and silver derivatives | |
Harada et al. | Synthesis and crystal structures of the chromium (II) and chromium (III) hexafluoroacetylacetonate complexes trans-Cr (hfac) 2 (thf) 2 and Cr (hfac) 3 | |
Jin et al. | Self-assembled 1D infinite inorganic [2] catenane and 2D sheet framework with calix [8] phenylazoimidazole and [4+ 4] metallomacrocyclic motifs based on silver and ditopic bis (imidazolyl) methane ligands | |
Choi et al. | In situ crystalline transformation of bis (halo) mercury (ii) coordination polymers to ionic chloro-bridged-bis (halo) mercury (ii) species via UV irradiation in chloroform media | |
Boudalis et al. | Tetranuclear iron (III) carboxylate clusters with 1, 10-phenanthroline and 2, 2′-bipyridine: a new [Fe 4 (μ 4-OHO)(μ-OH) 2] 7+ core | |
Huang et al. | Hydrotris (3, 4-diphenyl-5-methylpyrazol-1-yl) borate: Control of coordination number via an equatorial substituent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |